We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CORDIS WARNED FOR HOST OF GMP VIOLATIONS AS STENT MARKET COMPETITION HEATS UP
CORDIS WARNED FOR HOST OF GMP VIOLATIONS AS STENT MARKET COMPETITION HEATS UP
April 9, 2004
Johnson & Johnson subsidiary Cordis has been cited by the FDA for a series of current good manufacturing practice violations stemming from a postapproval inspection at five sites that produce the Cypher drug-eluting stent.